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Abstract Knowledge on children’s capacities to consent to
medical treatment is limited. Also, age limits for asking chil-
dren’s consent vary considerably between countries.
Decision-making on predictive genetic testing (PGT) is espe-
cially complicated, considering the ongoing ethical debate. In
order to examine just age limits for alleged competence to
consent in children, we evaluated feasibility of a standardized
assessment tool, and investigated cutoff ages for children’s
competence to consent to PGT. We performed a pilot study,
including 17 pediatric outpatients between 6 and 18 years at
risk for an autosomal dominantly inherited cardiac disease,
eligible for predictive genetic testing. The reference standard
for competence was established by experts trained in the rel-
evant criteria for competent decision-making. The MacArthur
Competence Assessment Tool for Treatment (MacCAT-T)
served as index test. Data analysis included raw agreement
between competence classifications, difference in mean ages
between children judged competent and judged incompetent,
and estimation of cutoff ages for judgments of competence.
Twelve (71 %) children were considered competent by the
reference standard, and 16 (94 %) by the MacCAT-T, with
an overall agreement of 76%. The expert judgments disagreed
in most cases, while the MacCAT-T judgments agreed in
65%.Mean age of children judged incompetent was 9.3 years
and of children judged competent 12.1 years (p=.035). With
90 % sensitivity, children younger than 10.0 years were
judged incompetent, with 90 % specificity children older than
11.8 years were judged competent. Feasibility of the
MacCAT-T in children is confirmed. Initial findings on age
cutoffs are indicative for children between the age of 12 and
18 to be judged competent for involvement in the informed
consent process. Future research on appropriate age-limits for
children’s alleged competence to consent is needed.
Keywords Sensitivity and specificity . Decision-making .
Minors . Genetic testing . Informed consent . Mental
competence
Introduction
Children from families in which a causative mutation has been
identified for autosomal dominantly inherited cardiac diseases
may be offered predictive genetic testing (PGT) at an age
when cardiologic surveillance and preventive treatment are
indicated (European Society of Human Genetics 2009; Borry
et al. 2009; Ross et al. 2013). In most cases the manifestations
of these cardiogenetic diseases and in particular sudden death
can effectively be postponed or prevented with lifestyle mod-
ifications, devices like an internal defibrillator or pacemaker,
or use of medication (Smets et al. 2008). There is some pre-
liminary evidence that such interventions might reduce risk in
children (Lashley 1999). However, the penetrance of the mu-
tations is variable and incomplete. For instance,
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approximately 50 % of the mutation carriers of LQTS will
develop symptoms (Priori et al. 1999). For inherited cardiac
diseases PGT in children is generally considered acceptable or
even part of recommended care (Charron et al. 2010; Europe-
an Society of Human Genetics 2009; Heart Rhythm Society
(HRS) & European Heart Rhythm Association (EHRA)
2011), and it can identify individuals at increased risk of or
in the early stage of a disease at a time when intervention can
reduce the risk of morbidity and mortality. This article does
not address the larger important ethical questions of the ap-
propriateness of PGT in children generally. Nevertheless, the
ethical debate underlines the complexity of the issue and con-
sequently the complexity of the individual’s decision on PGT.
To illustrate the impact that cardiogenetic diseases might
have, we will briefly describe the 5 syndromes dealt with in
this article. Long QT syndrome (LQTS) is characterized by a
prolongation of the corrected QT-interval on the electrocardio-
gram (ECG) and may lead to palpitations, dizziness, fainting,
seizure-like fits and sudden death. Symptoms can be triggered
by exertion, emotions, and loud noises in LQTS type 1 and 2,
and can occur at rest in LQTS type 3. Manifestations of the
symptoms can develop at all ages, but especially in LQTS
type 1 and 2 occur in childhood (Smets et al. 2008). Hyper-
trophic cardiomyopathy (HCM) is characterized by unex-
plained ventricular hypertrophy and is the most common
cause of sudden unexpected cardiac death in young adults,
particularly in competitive athletes. Other symptoms of
HCM are dyspnea, chest pain, syncope, arrhythmias,
thrombo-embolic events, and heart failure (Smets et al.
2008). Brugada syndrome (BS) is a disease with typical ab-
normalities on the ECG and an elevated risk of sudden cardiac
death. Fever as well as certain drugs can evoke the symptoms,
most commonly seen in men around the age of 40 (Vatta et al.
2002). Catecholaminergic polymorphic ventricular tachycar-
dia (CPVT) is a disease characterized by arrhythmias caused
by a release of catecholamines in case of emotional upheaval,
physical exercise or psychological stress (Priori et al. 2002).
The first symptoms can emerge in childhood or young adult-
hood. Arrhythmogenic right ventricular cardiomyopathy
(ARVC) is a disorder of the myocardium, that usually appears
in adulthood, which increases the risk of an arrhythmia. It may
not cause symptoms in its early stages, however, affected in-
dividuals may be at risk of sudden death, especially during
strenuous exercise (Tichnell et al. 2014).
When clinicians do believe testing is appropriate and “in
the best interest of the child” and provide testing tominors and
their families, they will invite them to counsel about the dis-
ease and PGT and to give their consent to the suggested test-
ing. This raises the question to what degree children under-
stand the risks and benefits of PGT and the complexity of the
decision, and can be deemed competent to give their consent.
It is postulated that more complex decisions or decisions
concerning a higher level of potential risk may require a
higher level of competence, however the level of risk and
complexity is not yet well quantifiable (Hein et al. 2015).
Informing children and gaining their cooperation has impor-
tant advantages: answering questions and helping the child to
understand what to expect will help the child to make sense of
the experience, prevent misunderstanding or resentment, and
increase compliance (Shaw 2001). In addition, a just assess-
ment of a child’s competence to consent is vital for striking a
proper balance in order to both protect children’s interests
when they are not fully able to do so themselves and to respect
their autonomy when they are able to exercise it.
In clinical practice, generally the term decision-making ca-
pacity is used to describe different levels of patients’ abilities,
and the term competence refers to the degree of capacity that is
sufficient to allow patients to make an autonomous medical
decision (Grisso et al. 1997). In medical practice, competence
to consent is generally assessed implicitly and absent a stan-
dard. Clinicians tend to judge a child competent if the child’s
decision conforms to their own ideas of what was in the child’s
best interest (de Vries et al. 2010). The reliability of unstruc-
tured competence assessments has been poor (Appelbaum
2007) and age standards prescribed by law are the guiding
principle in clinician’s competence assessments. Nevertheless,
these legal age limits for deeming a child competent to consent
vary widely between countries (Hein et al. 2012). In Europe
different domestic laws determine whether people are compe-
tent to consent to healthcare interventions (Stultiens et al.
2007). Some countries consider autonomous decision-
making lawful from the age of 18 onwards, and in other coun-
tries people are allowed to take healthcare decisions from a
fixed age below legal majority, for instance, 12 years in the
Netherlands and 15 years in Denmark (Stultiens et al. 2007).
Most Canadian provinces and Switzerland apply a flexible
system, stating that anyone who is capable can give informed
consent, whereby competence is evaluated on a case-by-case
basis (Stultiens et al. 2007). In the United States, generally
speaking, it often falls to parents or legal guardians to provide
informed permission for medical decisions, and children un-
der the age of 18 are to give assent (American Academy of
Pediatrics Committee on Bioethics 1995). Assent includes
that physicians give serious consideration to the developing
capacities of older children and adolescents for participating in
decision-making, and solicit their affirmative agreement
(American Academy of Pediatrics Committee on Bioethics
1995). In our study, in order to deal with discrepancies be-
tween the local law and international jurisdictions, we studied
children’s capacities for deciding on consent regardless of
their age.
The capacities of children to participate in medical decision
making remains inconclusive and there is not a well-
established assessment approach, neither have the legally set
age limits been systematically investigated. Generally, the ac-
cepted standard in adults for assessing capacity to make
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treatment decisions consists of an unstructured judgment by
an expert, trained in the four criteria that reflect the standards
to be weighed in most jurisdictions: understanding, reasoning,
appreciation, and expressing a choice (Hein et al. 2014a).
Empirical studies on children’s capacities to make treatment
decisions are very limited. As far as we know, only 3 studies
have been conducted using a structured instrument that ad-
dresses all four relevant criteria, which in all cases was the
MacArthur Competence Assessment Tool for Treatment
(MacCAT-T) (Grisso et al. 1997). Chenneville investigated
the MacCAT-T in a sample of youth with an average age of
17 years, with HIV (Chenneville et al. 2014). A limitation of
this study is that previously established cutoff scores were used
(Aydin and Sehiralti 2014) which were established in a popu-
lation of adult psychiatric patients and not evaluated in a sample
of minors. Turrell and colleagues used the MacCAT-T in a
comparative study on capacities to consent in adolescents with
anorexia nervosa and healthy controls and found group differ-
ences: adolescents with anorexia nervosa tended to experience
more problems in reasoning about treatment than healthy con-
trols (Turrell et al. 2011). Schachter and colleagues assessed
understanding by means of a modified version of the under-
standing section of MacCAT-T. Results suggested that the ma-
jority of adolescents with ADHDhave an understanding similar
to that of their parents (Schachter et al. 2011). None of these
studies tested the reliability and validity of the structured assess-
ment instrument against a reference standard. Empirical re-
search on children’s competence to consent is still a novel area.
Therefore, the aim of our pilot study is evaluating feasibil-
ity of a standardized competence assessment tool for children
in PGT by modifying the MacCAT-T (Grisso et al. 1997), and
initially investigating accuracy against a reference standard
and cutoff ages for competence to consent.
Methods
Participants
Participants were pediatric outpatients between 6 and 18 years
of age visiting the clinical genetics department at the Academic
Medical Center in Amsterdam, the Netherlands, who were pro-
spectively enrolled. They were referred by physicians for being
at risk for an autosomal dominantly inherited cardiac disease.
Exclusion criterion was not speakingDutch. The study protocol
was approved by the institutional review board and written
informed consent was obtained from all individual participants
included in the study, or a parent or legal guardian.
Instrumentation
As the index test for assessment of abilities related to compe-
tent consent, we used the MacCAT-T, developed by Grisso
and Appelbaum in 1998 (Grisso et al. 1997). PGT in fact
concerns diagnostic testing, however it takes place in a treat-
ment context and therefore the MacCAT-T is the most appro-
priate instrument. The MacCAT-T measures the four aspects
of decision-making capacities by operationalizing the four
criteria into a semi-structured interview format: (1) under-
standing the disclosed information about the nature of the
disease and the proposed intervention; (2) reasoning in the
process of deciding about the proposed intervention, with a
focus on abilities to compare alternatives in the light of their
consequences; (3) appreciation of the effects of the interven-
tion (or failure to undergo the intervention) on patient’s own
situation; and (4) expressing a choice about the intervention.
Information disclosure required for informed consent is com-
bined with an assessment of the patient’s capacities. In this
study the information disclosure was adapted to the specific
cardiogenetic disease that a participant was tested for. The
method provides scores for each subscale: 0–6 for understand-
ing, 0–4 for appreciation, 0–6 for reasoning, and 0–2 for ex-
pressing a choice. The method does not offer a total score or a
cutoff for competence, but the scores on the subscales need to
be weighed by the interviewer. The MacCAT-T takes approx-
imately 15 min administration time, and some additional mi-
nutes for scoring. It receives empirical support in adult popu-
lations of mentally compromised patients (Hein et al. 2014a).
The MacCAT-T was translated in Dutch, and translated back
in English, by a professional translator. The version used was
approved by the original author (T.G.). The Dutch version was
modified for children which included the use of simple lan-
guage to be understood by children of elementary school age.
The interview was read out aloud to participants to exclude
interference of children’s reading levels. Furthermore, in the
child version of the MacCAT-T we added questions on the
influence of social relationships (Hein et al. 2012). In the
reasoning domain, “How do you think your parents will feel
about you deciding to have this diagnostic test or deciding not
to have it? And how do you think your friends will feel about
it?” has been added (proprietary issues preclude publication of
the version used).
Although a gold standard for competence does not exist,
we examined whether using a structured assessment instru-
ment instead of an expert judgment would be possible without
compromising accuracy. Usually, agreement is poor between
unstructured clinical competence judgments, and often no bet-
ter than chance (Hein et al. 2014a). Providing clinicians with
information regarding the legal standards improves their judg-
ments and significantly increases the inter-rater agreement
(Hein et al. 2014a). These legal standards embody the four
capacities: to communicate a choice, to understand the rele-
vant information, to appreciate the medical consequences of
the situation, and to reason about treatment choices. Clinicians
aware of these relevant criteria are generally considered to
establish the reference standard (Hein et al. 2014a). However,
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limitations of this approach may include discordance of expert
competence judgments, leading to inconsistencies in the ref-
erence standard. Thus, poor performance of the MacCAT-T
could either result from imperfections in the reference stan-
dard, or from an inaccurate assessment of competence based
on the examiner’s use of the MacCAT-T.
Procedures
Children and parents were informed by a genetic counselor or
clinical geneticist on PGT (Christiaans et al. 2008), according
to the consensus documents on genetic testing in children of
the Dutch and European Societies of Human Genetics. The
counselling session was preceded by a telephone call from the
psychosocial worker with the parents to already discuss how
the children had reacted on the information provided by the
parents about the genetic disease, if they had experienced
symptomatic disease in close relatives and if there were any
psychosocial issues to be aware of in the counselling session.
The counselling session at the outpatient clinic comprised
issues necessary for informed decision-making, including
the characteristics of the disorder tested for, the possible treat-
ment options, the possible drawbacks of testing, and possible
psychosocial consequences. Parent(s) and childrenwere asked
if they consented to PGT. This conversation was videotaped
and served as the basis for establishing the reference standard
(see below). Usually at the same day, at most within 2 weeks,
an interviewer from a panel of experts (listed below) admin-
istered aMacCAT-T interview to the child. This interview was
also videotaped, and rated afterwards.
The panel of 7 experts (including I.M.H., P.W.T., I.C., and
R.J.L.L.) consisted of a clinical geneticist, child psychiatrists,
child psychologists, and a social worker. The experts were
trained in judging competence to consent by the 4 relevant
criteria, and jointly practiced through rating 3 videos of the
conventional informed consent conversation. In addition, the
experts were instructed on rating the MacCAT-T, and prac-
ticed together by rating 2 videos of MacCAT-T interviews.
Next, each member of the panel independently rated a number
of conventional informed consent conversation videos and a
number of MacCAT-T interview videos that were presented in
random order and reciprocally blinded. Each MacCAT-T in-
terview video was rated by 3 different experts. For all videos,
the experts gave their judgment consisting of 1 of the follow-
ing 4 categories: very likely competent, probably competent,
probably incompetent, and very likely incompetent. We con-
sidered competence to be present when an expert gave a judg-
ment of very likely or probably competent. The experts were
not informed about the age of the children. For establishing
the reference standard, each video from the conventional in-
formed consent conversation was rated by 2 different experts,
and also the clinical geneticist gave his/her judgment of the
child’s competence, adding up to 3 judgments.
The cognitive level of the children was assessed by the
Wechsler Nonverbal Scale of Ability short version (WNV).
The WNV is a clinical instrument for examining cognitive
capacities of children and adolescents aged 4 to 21, which is
suitable for the general population as well as for children with
cultural, linguistic, educational or socio-economic varying
backgrounds. The subtests do not invoke verbal capacities as
instructions are made by pictograms, and the validity and re-
liability of the short version are good. The WNV was admin-
istered by trained certified professionals (special education or
psychology graduates) under supervision of a senior
professional.
Data analysis
Competence was considered present when at least 2 out of 3
judgments were positive, for both the expert judgments estab-
lishing the reference standard, and the ratings based on the
MacCAT-T. Agreement between the reference standard and
the MacCAT-T based competence classification (accuracy of
the MacCAT-T-based competence classifications) was
expressed as the raw percentage agreement.
Reproducibility of the MacCAT-T total and subscale sum
scores as obtained by 3 ratings on the MacCAT-T, was esti-
mated using intraclass correlation coefficients (ICC, model 1,
single measure).
Agreement between the 3 ratings of the experts, and be-
tween the 3 ratings based on the MacCAT-T, was expressed as
the raw percentage.
Independent samples t-test was used to test the difference in
mean ages between competent and incompetent children on
the reference standard. Best discriminating cutoff ages for
competence on the reference standard were estimated using
receiver operator characteristic curve (ROC) analysis, with
area under the curve (AUC) exceeding .70 considered ade-
quate for the estimation of age cutoff.
Results
Between January 1, 2013 and January 1, 2014, 23 children
were eligible. Of them, 6 did not participate for different rea-
sons, concerning time constraints in 2 cases, elevated stress in
2 cases, and no clear reason in 2 cases. Non-participants were
child as incompetent and the examiners using the MACAT-T
did not. The other way around did not occur. Overall agree-
ment was 76 %.
MacCAT-T total scores inter-rater agreement coefficient
was .95. Inter-rater agreement on subscale scores were .93
for understanding, .91 for appreciation, .91 for reasoning
and total agreement for choice.
Agreement between all 3 ratings on the reference standard
occurred in 8 cases (47 %), and on the MacCAT-T based
classification the 3 ratings showed agreement in 11 cases
(65 %).
On the reference standard, mean age of children judged
incompetent was 9.3 years and for those judged competent
12.1 years (p=.035).
Age as a predictor of competence on the reference standard
showed AUC .80 (95 %; .55–1.00). Cutoff age for being
judged competent with 90 % sensitivity was 10.0 years and
with 90 % specificity 11.8 years.
Discussion
Results of the current study confirm feasibility and show ini-
tial indications for reliability and validity of the MacCAT-T in
children eligible for PGT: inter-rater agreement on scores was
high, and agreement between MacCAT-T based competence
classifications and the reference standard was adequate, al-
though not decisive. By using the MacCAT-T, children were
more often classified as competent than by the reference
standard.
Age cutoffs for presumed competence to consent to PGT in
this sample, based on the reference standard, were: children of
11.8 years and above were very likely to be considered com-
petent to consent to PGT, and children of 10.0 years and
younger were most probably not competent to consent. Earlier
work showed that the modified MacArthur Competence As-
sessment Tool for Clinical Research was valid and reliable for
use in children (Hein et al. 2014b) and in a population of 161
pediatric patients eligible for research participation, children
older than 11.2 years were generally found competent to con-
sent and children younger than 9.2 years incompetent (Hein
et al. 2014b). Obviously, children’s competence to consent to
treatment and their competence to consent to clinical research
are not the same. It has been stated that consent to participa-
tion in research must be a more stringent process than consent
to treatment, because the research participants are generally
not asked to participate for their individual benefit, but to help
improve general health care (Lind et al. 2003). Additionally,
the level of complexity and risk of the decision on PGT, which
has not been quantified in this study, may affect the level of
Table 1 Baseline characteristics and outcomes of competence classifications on reference standard and MacCAT-T
Child no. Disease
tested fora
Age in years
(male/female)
Expert classification
(competent: incompetent)
MacCAT-T score,
(subscale scores U/A/R/C)b
MacCAT-T classification
(competent: incompetent)
1 HCM 6 F I (0:3) 29 (21/2/3/2) C (2:1)
2 LQTS 7 M I (0:3) 30 (21/4/4/2) I (1:2)
3 BS 9 M I (0:3) 36 (23/4/7/2) C (3:0)
4 HCM 9 M C (3:0) 32 (18/4/8/2) C (3:0)
5 HCM 10 M C (2:1) 31 (21/4/4/2) C (2:1)
6 HCM 10 M C (2:1) 35 (22/4/7/2) C (3:0)
7 HCM 10 F C (3:0) 38 (25/3/8/2) C (3:0)
8 HCM 10 F C (2:1) 36 (23/2/9/2) C (3:0)
9 HCM 11 M C (2:1) 36 (22/4/8/2) C (3:0)
10 HCM 11 F I (1:2) 29 (18/2/7/2) C (2:1)
11 HCM 11 M I (1:2) 38 (25/4/7/2) C (3:0)
12 HCM 12 M C (2:1) 30 (20/4/4/2) C (2:1)
13 CPVT 12 M C (2:1) 38 (24/4/8/2) C (3:0)
14 CPVT 13 F C (2:1) 34 (24/3/5/2) C (2:1)
15 LQTS 13 F C (3:0) 40 (25/4/8/2) C (3:0)
16 ARVC 14 F C (3:0) 40 (26/4/8/2) C (3:0)
17 ARVC 17 M C (3:0) 38 (25/4/7/2) C (3:0)
76 % agreement
MacCAT-T vs expert
aARCV arrhythmogenic right ventricular cardiomyopathy, BS Brugada syndrome, CPVT catecholaminergic polymorphic ventricular tachycardia, HCM
hypertrophic cardiomyopathy, LQTS long QT syndrome
bMean scores from three raters, U understanding, A appreciation, R reasoning, C choice
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competence required and thereby the resulting age-limit in this
specific population. Nevertheless, the fact that the present
findings are consistent with previously found age cutoffs in
children regarding their competence to consent to clinical re-
search, increases support for the results.
The rate of disagreement between the competence ratings
was high, both for expert judgments and for the MacCAT-T
based judgments. Even so, where the expert judgments
disagreed in most cases, the use of the MacCAT-T led to an
increased agreement. Factors that explain the high rate of dis-
agreement between judgments, no matter what assessment
method was used, might be related to normative aspects and
difficulties in assessing developmental aspects in children.
Although decision-making competence may be a matter of
minor differences (Buchanan and Brock 1990), the compe-
tence judgments require a definitive assessment of whether
competence is present or not. It is still under debate whether
a threshold for competence can be established based on the
sum of the different decision-making capacities (Vellinga
2006). Especially in children, development of different do-
mains relevant for competent decision-making may not occur
simultaneously, which may complicate the assessment of a
child’s competence.
Practice Implications
For the clinical practice of PGT, no definitive conclusions can
be drawn from this study’s results. Yet, the results indicate
preliminarily that clinical judgments of competence to consent
to treatment can be present in children under the age of 18,
even when it concerns a complex decision regarding PGT.
Moreover, in our small sample, all children of 12 years and
above were considered competent to consent to PGT, indepen-
dent of the assessment method used. Taking into account that
understanding of the relevant medical information is critical
for competent decision-making, it deserves attention to supply
even young children with adequate information tailored to
their developmental stage and comprehension level (Hein
et al. 2012) in order to optimally involve them in the informed
consent process.
Study Limitations
A salient limitation of this study concerns the small sample
size and wide age range, which complicate an exhaustive
analysis of the data. Furthermore, poor reliability among ex-
perts forming the reference standard is a significant limitation,
as it was the benchmark that the MacCAT-T results were com-
pared to. The fact that all but 1 child in the sample was rated as
competent by using the MacCAT-T should be noted, as this
could relate to limited utility when using the MacCAT-T. Al-
though participants of a wide age range were recruited, the
obtained sample contains for the greater part children between
9 and 14 years of age, thus the generalizability of the results
beyond this age group must be considered with caution.
Research Recommendations
More empirical research on children’s capacities to consent to
treatment is needed, in order to provide objective data to un-
derpin a just age limit for alleged competence. In addition, an
accurate assessment instrument is needed to substantiate com-
petence judgment in individual cases. Exploration of the psy-
chometric properties of the MacCAT-T in a larger sample can
enable estimation of a cutoff score above which competence is
more likely. More extended research should be directed espe-
cially at pediatric populations where competence issues can
become problematic. Examples of such situations comprise
children older than the legal age for competence who refuse
a recommended medical treatment, for instance children with
anorexia nervosa who refuse tube feeding, or children with
renal insufficiency who refuse dialysis. Also children younger
than the legal age for competence who wish for a certain treat-
ment, like children eligible for medical interventions for gender
dysphoria, must be considered. Future research should address
the issue of the presumed higher requirements for competence
when decisions are more complex or carry more potential risk.
Conclusion
Our present results confirm that the MacCAT-T is promising
for standardizing competence assessment in children in treat-
ment situations. The strength for using the MacCAT-T in-
cludes high interrater agreement, and the consistency in
MacCAT-T results compared to the expert judgments lends
additional support to the use of the instrument. The reliability
and validity of the MacCAT-T must be demonstrated in a
larger sample of children.
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